Goserelin acetate, commonly known as Zoladex, is a gonadotropin-releasing hormone (GnRH) agonist used in specialist hormone treatment. Drug identity. It is supplied as an implant, not an oral tablet. UK formulation.
Confidence is high for the documented product identity and attributed licence/safety instructions. Independent comparative treatment benefit is not established by this guide’s finance-screened evidence: seller label outcomes are excluded, and educational sources do not clear their underlying trials.
- Goserelin, Zoladex and Zoladex LA require product-specific instructions.
- Initial hormone flare can worsen cancer symptoms; new neurological or urinary symptoms need immediate review.
- UK and US breast indications differ for the longer-acting implant.
- Stopped periods do not prove contraception or ovarian suppression.
- England dispensing items measure usage in one setting, not worldwide popularity or benefit.
Table of contents
- Evidence summary
- Implants, names and jurisdiction
- Hormone suppression and early flare
- Breast endocrine care and ovarian function
- Symptoms, bone health and supplements
- England prescribing volume and evidence limits
- Urgent symptoms: do not wait for the next implant
- Medicine interactions and heart rhythm
- Pregnancy, contraception and breastfeeding
- Administration, missed appointments and monitoring
- Animal evidence and commercial source boundaries
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Drug identity | NCI | Page receipts unclosed | Names/class only. |
| Breast care | NCI education | Trials unclosed | Attributed context. |
| UK/US | UK LA; US 10.8 | Sellers | Licences differ. |
| Severe skin | US 3.6 | Seller | Safety instruction, not incidence. |
| Cord symptoms | NICE | Committee chain unclosed | Emergency recognition. |
| Usage | England Table 7 | Agency finance below | Items, not benefit. |
Implants, names and jurisdiction
UK Zoladex 3.6 mg lists selected prostate and ER-positive breast-cancer uses in pre/perimenopausal women. Its noncancer uses include endometriosis, fibroid-related preoperative anaemia, endometrial thinning and assisted reproduction under specialist care. UK indications. These are different clinical pathways, not a home-use menu.
UK Zoladex LA 10.8 mg includes selected prostate and ER-positive breast-cancer settings. LA licence.
US 10.8 mg is not indicated for women; its oncology indications are prostate cancer. US product restriction.
The NCI’s US drug entry describes selected prostate treatment and palliative advanced breast treatment in pre/perimenopausal women. US educational scope. Palliative treatment addresses cancer and symptoms; it does not mean cure.
Reseligo appears as a goserelin implant in a dated, commercially sponsored EU record. Historical alias. That record does not verify every currently sold product.
Hormone suppression and early flare
GnRH agonists initially increase luteinising and follicle-stimulating hormones, then sustained exposure lowers testosterone or oestrogen production. Mechanism.
Prostate flare can worsen bone pain, urinary obstruction or cord compression. Antagonists act differently. Antiandrogen cover requires clinician direction; do not change medicines yourself. Flare context.
Breast endocrine care and ovarian function
Breast endocrine choices depend on oestrogen/progesterone receptor findings. Drug-induced ovarian suppression differs from permanent surgical removal. With functioning ovaries, an aromatase inhibitor requires ovarian suppression; NCI also describes selected male advanced-breast contexts. Endocrine-care distinctions.
Confirm ovarian suppression before an aromatase inhibitor and maintain it. No periods after chemotherapy do not establish menopause. Precaution.
Symptoms, bone health and supplements
The LA patient leaflet lists hot flushes, sweating, sexual difficulties, vaginal dryness, mood changes and injection reactions. Some symptoms can persist after stopping. Persistent or troubling symptoms need the treating team’s help. Patient safety information.
Androgen deprivation affects bone, muscle and metabolism; review bone health rather than assuming a universal supplement. Class effects.
Disclose supplements and complementary remedies; they should not replace or delay cancer care. Non-replacement and disclosure safety. No independent goserelin-specific supplement benefit is established here.
England prescribing volume and evidence limits
The original FY2025/26 England Table 7 records 244,817 goserelin-acetate items, BNF code 0803042K0. Actual chemical-substance row 1032.
PCA describes community dispensing in England. Publication setting. Hospital-issued prescriptions dispensed in the community are included; hospital dispensary supplies are excluded. Indication is not recorded. Original methods.
Items are not unique patients or doses. The malignant-disease BNF grouping does not establish that every item treated cancer. Usage cannot show individual benefit, global popularity or which product is best. No finance-cleared head-to-head outcome verdict is supplied.
Urgent symptoms: do not wait for the next implant
New weakness, walking difficulty, numbness or bladder/bowel dysfunction in someone with cancer can indicate cord compression. Seek immediate specialist or emergency assessment. NICE oncology-emergency recognition.
After implantation, abdominal pain or swelling, breathlessness, dizziness or altered consciousness can signal serious injection-related bleeding: obtain immediate medical help. Vascular-injury warning.
Progressive rash, blistering, peeling, mouth/eye lesions, fever or swollen glands need medical attention right away. Clinicians interrupt treatment; confirmed severe reactions require permanent discontinuation. March 2026 warning. Do not remove the implant yourself.
Call your local emergency number for sudden throat/tongue swelling, serious breathing difficulty or collapse. Anaphylaxis triage.
Squeezing chest pain, spreading pain or severe breathlessness can be an emergency. Heart-attack warning. Severe breathing difficulty, chest/upper-back pain or collapse also needs emergency assessment; do not drive yourself. Pulmonary-embolism triage.
If you cannot keep yourself or someone else safe, seek emergency help immediately. Mental-health emergency action.
Sudden severe headache with vomiting, visual change or unconsciousness needs urgent assessment; the patient leaflet describes rare pituitary bleeding. Neurological warning.
Medicine interactions and heart rhythm
Review QT (heart electrical recovery) risks with antiarrhythmics, methadone, moxifloxacin and antipsychotics. Interaction assessment.
US 10.8 mg precautions include ECG (electrocardiogram)/electrolyte assessment for QT risk and glucose/cardiovascular monitoring in men. Monitoring. No individual test schedule is supplied.
Pregnancy, contraception and breastfeeding
The UK LA leaflet says not to use it in pregnancy or breastfeeding. Stopped periods are not a reliable pregnancy-prevention plan; agree nonhormonal contraception and after-treatment precautions with the team. UK restrictions.
US 3.6 mg contraindicates pregnancy except a narrow palliative advanced-breast context; positive tests need immediate specialist review. Feeding requires a clinician’s drug-versus-nursing assessment; human milk data are unavailable. US wording.
Confirm the actual implant’s feeding restrictions with your team; do not invent a milk-discard interval.
Administration, missed appointments and monitoring
A doctor or nurse administers the implant. If an appointment is missed or earlier/later than expected, contact the service. Patient instructions. Do not administer an extra implant or convert between strengths yourself.
A lower PSA (prostate-specific antigen) is not permission to stop. Cancer can progress despite low testosterone; androgen deprivation may remain part of combination care. Ongoing care.
Persistent vaginal bleeding or marked thirst needs review, including possible raised calcium in metastatic breast disease. Symptom assessment.
Animal evidence and commercial source boundaries
The UK label includes animal findings. Preclinical section. These do not establish human benefit or quantify individual pregnancy risk.
AstraZeneca’s 2025 filing traces revenue, its UK subsidiary and HQ. Parent filing.
Its 2017 announcement documents TerSera’s US/Canada rights and sales-linked payments to AstraZeneca. Historical agreement.
GTCR’s Winter 2025 report describes its TerSera partnership and a 2023 continuation vehicle. Actually read backer report. These records trace interests; they do not verify every current shareholder, fund investor, plant, product receipt or trial allocation.
Funding and source roles
Research funding at a glance
31 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI: goserelin dictionary | Public/gift routes below; page/reviewer/trial receipts unclosed. | United States; Bethesda, Maryland. | Tier 2 education, provisional. | C — Update date unexposed; clinical accountability, no independent outcome clearance. |
| NCI: goserelin acetate | Public/gift routes below; page/reviewer/trial receipts unclosed. | United States; Bethesda, Maryland. | Tier 2 education, provisional. | C — 7 January 2025; clinical accountability, no independent outcome clearance. |
| NCI: prostate hormone therapy | Public/gift routes below; page/reviewer/trial receipts unclosed. | United States; Bethesda, Maryland. | Tier 2 education, provisional. | C — 4 October 2024; clinical accountability, no independent outcome clearance. Outdated intermittent-trial statement excluded. |
| NCI: breast hormone therapy | Public/gift routes below; page/reviewer/trial receipts unclosed. | United States; Bethesda, Maryland. | Tier 2 education, provisional. | C — 23 September 2026; clinical accountability, no independent outcome clearance. |
| Zoladex 3.6 mg UK SmPC | AstraZeneca UK commercial holder; parent trace below. | United Kingdom; Cambridge. | Tier 4 seller. | D — text 27 March 2024; licence/safety duties, efficacy excluded. |
| UK LA SmPC | AstraZeneca UK; finance below. | UK; Cambridge. | Tier 4 seller. | D — April 2023; efficacy excluded; trial receipts unclosed. |
| Zoladex 3.6 mg leaflet | AstraZeneca UK; finance below. | UK holder: Cambridge; stated manufacturer: Macclesfield. | Tier 4 seller. | D — revised May 2022; safety duties. Not the newer professional label. |
| Zoladex LA leaflet | AstraZeneca UK; finance below. | UK holder: Cambridge; stated manufacturer: Macclesfield. | Tier 4 seller. | D — revised October 2022; safety duties. Incidental infertility wording does not establish an LA licence. |
| US 3.6 mg label | TerSera; backer trace below. | US; distributor Deerfield, Illinois. | Tier 4 seller. | D — March 2026; skin warning September 2025. Safety, efficacy excluded. |
| US Zoladex 10.8 mg label | TerSera commercial issuer; finance below. | United States; distributor Deerfield, Illinois. | Tier 4 seller. | D — March 2026. Product-specific licence/safety; predicted comparable outcomes excluded. |
| AstraZeneca 2025 report | Medicine sales, alliance/collaboration revenue; UK subsidiary wholly owned. | England/Wales parent; HQ 1 Francis Crick Avenue, Cambridge CB2 0AA. | Tier 4 commercial filing. | D — selected audited financial/HQ sections; trial and ultimate-shareholder chains unclosed. |
| AstraZeneca–TerSera agreement | 2017 US/Canada rights transfer; upfront, milestones and sales-linked payments to AstraZeneca. | United Kingdom issuer; United States/Canada rights. | Tier 4 commercial announcement. | D — 31 March 2017. Contract reporting incentive; current receipts or unchanged terms not established. |
| GTCR Winter 2025 report | Management partnership created TerSera in 2016; 2023 single-asset continuation vehicle funded it. | US; TerSera Lake Forest (2025); GTCR Chicago address traced separately. | Tier 4 interested backer. | D — selected printed page 29 read. Investor-growth incentives; current cap table, limited partners, allocations and full TerSera accounts unclosed. |
| EU register: historical Reseligo | Novartis Pharma AG commercial sponsor/support; Alvogen holder recorded for Polish-authorised Reseligo. | Italy record; sponsor Switzerland; Poland product authorisation. | Tier 4 industry project. | D — entered 22 January 2021; transitioned. Registration accountability; no current availability, ownership or efficacy inference. |
| NHS: anaphylaxis | National-site policy below; named reviewer/study payments unclosed. | United Kingdom; national NHS website. | Tier 2 safety context, provisional. | C — 21 June 2023; June 2026 deadline passed. Clinical accountability; no goserelin-event rate inferred. |
| NHS: heart attack | National-site policy below; named reviewer/study payments unclosed. | United Kingdom; national NHS website. | Tier 2 safety context, provisional. | C — 31 March 2026. Clinical accountability; no goserelin-event rate inferred. |
| NHS: pulmonary embolism | National-site policy below; named reviewer/study payments unclosed. | United Kingdom; national NHS website. | Tier 2 safety context, provisional. | C — 25 May 2023; May 2026 deadline passed. Clinical accountability; no goserelin-event rate inferred. |
| NHS: urgent mental-health help | National-site policy below; named reviewer/study payments unclosed. | United Kingdom; national NHS website. | Tier 2 safety context, provisional. | C — 26 April 2023; April 2026 deadline passed. Clinical accountability; no goserelin-event rate inferred. |
| NICE NG234: cord-compression signs | Institutional trace below; committee interests and trials unclosed. | United Kingdom; NICE, Manchester/London. | Tier 2 guidance, provisional. | C — 6 September 2023. Actual indexed final Box 1/1.3.2 read; direct access blocked. No treatment algorithm. |
| NICE 2025/26 accounts | DHSC grant-in-aid; NHS England support; appraisal/advice, commercial and research income. NG234 allocation unknown. | United Kingdom; Manchester/London. | Tier 3 financial report. | B, provisional — selected saved original pages 30–31 read previously. Accountability and assessment-income interests; no committee/trial clearance. |
| NCCIH: cancer complementary approaches | NCCIH public/gift routes below; named update contributors and underlying trial receipts unclosed. | United States; Bethesda, Maryland. | Tier 2 safety context, provisional. | C — October 2021; dated clinical accountability. No independently established goserelin-adjunct benefit adopted. |
| NCI: budget | Congressional appropriations through HHS/NIH. | United States; federal agency. | Tier 3 financial self-report. | B, provisional — 14 May 2026; enacted FY26 distinguished from requests. Budget accountability; exact page/reviewer/trial allocations unclosed. |
| NCI: gifts | Gift Fund accepts donations and research designations; company-name field is not proof of a particular receipt. | United States; Bethesda, Maryland. | Tier 3 institutional self-report. | B, provisional — 27 August 2025. Financial accountability; donor identities, amounts and page allocations not cleared. |
| NHSBSA: PCA 2025/26 | Agency institutional finance below; no disease-specific indication recorded. | England; NHSBSA publication. | Tier 2 public statistics, provisional. | B, provisional — June 2026. Administrative accountability; no clinical outcome verdict. |
| PCA original Table 7 | NHSBSA dataset; no manufacturer outcome claim. | England community dispensing. | Tier 2 administrative data, provisional. | B — FY2025/26 row 1032, code 0803042K0: 244,817 items. Not patients, doses, cancer-only or global use. |
| PCA original methodology | NHSBSA compilation; agency finance separately traced. | England; June 2026 methodology. | Tier 2 statistics context, provisional. | B — defined community coverage; hospital-issued community dispensing included. No prescribing-indication or comparative-effectiveness data. |
| NHSBSA 2025/26 accounts | DHSC-funded services and service charges; exact PCA allocation unresolved. | United Kingdom; Newcastle upon Tyne. | Tier 3 financial report. | B, provisional — actual saved original selected pages 132–133/143 previously read. Financial accountability; no manufacturer/trial clearance. |
| NHS content policy | DHSC funds the national website; policy rejects advertising and corporate sponsorship. | United Kingdom; national website, not every provider. | Tier 3 institutional self-report. | B — clinical-signoff/interests policy; specific receipts unknown. October 2022, October 2025 deadline passed; historical NHS Digital wording. |
| NCCIH appropriations history | Congressional appropriations; the displayed table ends at FY2024. | United States; Bethesda, Maryland. | Tier 3 institutional self-report. | B, provisional — actual table read. Fiscal accountability; no FY2026 enacted total or disease-page allocation inferred from it. |
| NCCIH Gift Fund | Authorised donations/bequests; conditional research or unconditional mission gifts separate from appropriations. | United States; Bethesda, Maryland. | Tier 3 institutional self-report. | B, provisional — actual process read. Authority is not evidence of named receipts, contributor payments or page allocations. |
| GTCR: own address | Private-equity investor; individual product allocations unclosed. | US; 300 N. LaSalle St., Suite 5600, Chicago, Illinois 60654. | Tier 4 commercial self-report. | D — current indexed own footer read; direct body blank. Address only; marketing and cap-table assertions excluded. |
Frequently asked questions
Is goserelin chemotherapy? It is hormone-directed treatment. The NCI distinguishes it from chemotherapy. Treatment distinction. A cancer plan can involve more than one treatment type.
Does England’s count identify only cancer treatment? No. Indication is not recorded. Dataset limit.
What should I do after a missed appointment? Contact the service instead of arranging an extra implant yourself. Appointment advice.
Does a lower PSA prove cure? No. Discuss response and continuing care with the cancer team.
Does the US longer-acting implant have the UK breast indication? No. The US 10.8 mg label explicitly says it is not indicated for women. Jurisdiction boundary.
Sources and funding notes
Selected primary clinical and financial sections were read; no complete trial, shareholder or investor audit is claimed. NICE recognition was available in the index, with direct access blocked. No treatment algorithm is supplied.
The NCI intermittent-trial statement is not adopted.
US 10.8 mg predictions of comparable outcomes are excluded.
No personal dose, implant conversion, injection technique, fertility regimen, numerical efficacy claim or breastfeeding schedule is supplied. Animal and cell efficacy is excluded.
- NCI: goserelin dictionary — Active name and class.
- NCI: goserelin acetate — US educational indication context.
- NCI: prostate hormone therapy — Flare and continued specialist care.
- NCI: breast hormone therapy — Receptor and ovarian-function distinctions.
- Zoladex 3.6 mg UK SmPC — UK indications and formulation identity.
- UK LA SmPC — Breast, ovarian, QT context.
- Zoladex 3.6 mg leaflet — Injection-injury warning and missed appointments.
- Zoladex LA leaflet — Symptoms and UK pregnancy/feeding restrictions.
- US 3.6 mg label — Severe skin, pregnancy, feeding and other precautions.
- US Zoladex 10.8 mg label — US male scope and metabolic/cardiac monitoring.
- AstraZeneca 2025 report — Parent ownership, revenue and HQ.
- AstraZeneca–TerSera agreement — Historical commercial-rights and payment route.
- GTCR Winter 2025 report — Documented private-equity backing.
- EU register: historical Reseligo — Dated alias only, no trial outcome.
- NHS: anaphylaxis — Severe-allergy emergency triage.
- NHS: heart attack — Acute chest-pain triage.
- NHS: pulmonary embolism — Severe breathing/chest symptoms.
- NHS: urgent mental-health help — Immediate safety-risk escalation.
- NICE NG234: cord-compression signs — Cancer emergency recognition.
- NICE 2025/26 accounts — Institutional channels and identity.
- NCCIH: cancer complementary approaches — Disclosure and non-replacement safety.
- NCI: budget — Public appropriation route.
- NCI: gifts — Separate gift authority/process.
- NHSBSA: PCA 2025/26 — Dispensing publication context.
- PCA original Table 7 — Exact code/item row.
- PCA original methodology — Coverage and indication limits.
- NHSBSA 2025/26 accounts — Agency revenue and HQ.
- NHS content policy — National-site funding/editorial process.
- NCCIH appropriations history — Historical public funding.
- NCCIH Gift Fund — Separate voluntary funding authority.
- GTCR: own address — Separate issuer location only.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.